|
AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Breztri Aerosphere is approved by the US Food & Drug Administration as a maintenance treatment for asthma in patients 12 years and older. Breztri is a fixed-dose triple-combination therapy. It already was approved by the FDA in 2020 for the treatment of adults with chronic obstructive pulmonary disease. Astra says the new indication follows trials in which Breztri showed a ‘statistically significant and clinically meaningful improvement in lung function’. Astra notes that Breztri is a maintenance therapy and isn’t meant to replace a rescue inhaler to relieve sudden breathing problems. It says filings for Breztri in asthma are under review in the EU, Japan and China. Current stock price: 13,830.00 pence, down 1.0% on Tuesday morning in London 12-month change: up 31% Copyright 2026 Alliance News Ltd. All Rights Reserved.
|
